Serious Risks Hypoglycemia (low blood sugar): Rare on its own, but a potential risk when combined with insulin or insulin-stimulating drugs
Related methods have assessed total H 2 S after its release by reduction of biological samples, followed by trapping with ethyliodoacetate 38 or monobromobimane 34,35
Mller A, Gabriel H, Sies H (1985) A novel biologically active selenoorganic compoundIV: protective glutathione-dependent effect of PZ 51 (Ebselen) against ADP-Fe induced lipid peroxidation in isolated hepatocytes
Start: 200 mcg once daily Increase: Add ~200 mcg every 2 weeks as tolerated Target Range: 400600 mcg once daily Frequency: Once daily Cycle Length: Typically 812 weeks Timing: Any consistent daily time
The compound has been studied in trials lasting up to 68 weeks, which provides useful medium-term data but leaves questions about effects beyond 2 years of continuous use
The Yellow Card Scheme ( operated by the MHRA, allows patients and healthcare professionals to report suspected side effects, contributing to ongoing medication safety monitoring